Abbott Initiates Urgent Libre 3 Sensor Correction After Manufacturing Defect
The Abbott Recall announced on November 24, 2025, affects approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring sensors distributed across the United States. This major Abbott Recall stems from a manufacturing defect that may cause incorrect low glucose readings, posing serious health risks to diabetes patients. Medical device manufacturer Abbott Laboratories disclosed that the Abbott Recall has been linked to 736 severe adverse events globally, including 57 cases in the United States and seven deaths outside the country, though no fatalities were reported domestically.
The Abbott Recall stems from internal testing that identified a manufacturing defect affecting sensors used by millions of diabetes patients who rely on continuous glucose monitoring technology for real-time blood sugar management. According to the company’s official statement, the faulty sensors have been linked to 736 severe adverse events globally, including 57 cases in the United States and seven deaths outside the country, though no fatalities were reported domestically.
Manufacturing Defect Isolated to Single Production Line
Abbott’s diabetes care division traced the problem to one production line among several facilities manufacturing Libre 3 Sensor products. The company emphasized that it has identified and resolved the root cause of the malfunction, enabling continued production without anticipated supply disruptions. Approximately half of the 3 million affected sensors have either expired or been used, according to Abbott’s estimates.
The nature of the defect involves sensors providing undetected false low glucose readings over extended periods. Such inaccuracies can prompt diabetes patients to make incorrect treatment decisions, including excessive carbohydrate intake or delayed insulin administration. These actions pose serious health risks, including hypoglycemia, loss of consciousness, and potentially fatal complications.
Patient Safety Protocol and Replacement Program
Abbott has established a dedicated verification website at www.FreeStyleCheck.com where consumers can determine whether their sensors are affected by entering serial number information. The company is offering free replacements for all potentially impacted devices and has deployed customer service representatives available seven days per week from 8 a.m. to 8 p.m. Eastern Time at 1-833-815-4273, with 24/7 live chat support available through the company’s website.
Patients currently using or possessing confirmed affected sensors are advised to immediately discontinue use and dispose of the devices properly. Abbott recommends that users rely on traditional blood glucose meters or the built-in meter in the FreeStyle Libre 3 reader to guide treatment decisions when sensor readings contradict physical symptoms or expectations.
Limited Scope Within Product Portfolio
The Abbott Recall specifically targets FreeStyle Libre 3 and Libre 3 Plus sensors manufactured from the identified production line. Importantly, FreeStyle Libre 3 readers and mobile applications remain unaffected by the correction. Other products in Abbott’s continuous glucose monitoring portfolio, including FreeStyle Libre 14-day, FreeStyle Libre 2, FreeStyle Libre 2 Plus, and FreeStyle Libre Pro sensors, are not impacted by this manufacturing issue.
The global healthcare technology leader, which employs 114,000 people across more than 160 countries, has extended the medical device correction to international markets where Libre 3 Sensor products are distributed. The company has notified regulatory authorities worldwide as part of its compliance obligations.
Industry Implications for Diabetes Technology
This development arrives at a critical juncture for Abbott, which has positioned itself as a dominant force in the continuous glucose monitoring market. The FreeStyle Libre 3 system, which received FDA clearance in May 2022, represents the company’s latest-generation diabetes management technology. The sensor’s compact design and smartphone connectivity have made it a popular choice among the estimated 37 million Americans living with diabetes.
The recall underscores the ongoing quality control challenges facing medical device manufacturers as continuous glucose monitors become increasingly sophisticated. Abbott’s swift action in implementing the correction demonstrates the company’s commitment to patient safety, though questions remain about how manufacturing oversight allowed defective sensors to reach consumers initially.
For diabetes patients, the incident highlights the continued importance of backup blood glucose testing methods, even when using advanced continuous monitoring technology. Healthcare professionals recommend that patients never rely solely on CGM readings when symptoms suggest discrepancies, particularly when making critical treatment decisions regarding insulin administration.
Abbott has assured stakeholders that its multiple production lines will maintain adequate supply levels throughout the replacement process, minimizing disruption to the millions of patients who depend on continuous glucose monitoring for daily diabetes management.
